Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyxeos plus Gilteritinib in relapsed or refractory FLT3-mutated AML
NCT05024552Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2022
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Moffitt Cancer Center. Started Feb 2022; status: recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05024552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024552.